1Faculty of Environment and Information Studies, Keio University, Kanagawa, Japan
2Department of Public Health Sciences, University of California, Davis, School of Medicine, Davis, CA, USA
Copyright © 2016 The Korean Society for Preventive Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICT OF INTEREST
The authors have no conflicts of interest associated with the material presented in this paper.
Database1 | Keywords for search |
---|---|
PubMed/MEDLINE | ("costs and cost analysis"[MeSH terms] OR "cost benefit analysis"[MeSH terms] OR "cost effectiveness" OR "cost utility") AND ("telemedicine"[MeSH terms] OR telecare OR telehealth OR e-health) AND Japan |
Web of Science | TS = ("cost$analysis" OR "cost*benefit" OR "cost*effectiveness" OR "cost*utility" OR "economic evaluation") AND TS = (telemedicine OR tele*care OR tele*health OR e*health) AND TS = (Japan*) |
IEEE Xplore | ("cost analysis" OR "cost benefit" OR "cost effectiveness" OR "cost utility" OR "economic evaluation") AND (telemedicine OR telec are OR telehealth OR e-health) AND Japan |
Ichushi-Web2 | (in Japanese) Within "Original Article" category, used ("cost analysis" OR "cost benefit" OR "cost effectiveness" OR "cost utility" OR "economic evaluation") AND (telemedicine OR telecare OR telehealth OR e-health) |
CiNii Articles2 | (in Japanese) ("cost analysis" OR "cost benefit" OR "cost effectiveness" OR "cost utility" OR "economic evaluation") AND (telemedicine OR telecare OR telehealth OR e-health) |
Author (published year) [Ref] language | Service setting & location | Clinical discipline | Study design | Econ Eval type | Quality assess1 | Perspective | Time horizon (discount) depreciation | Sample size | Cost measurement | Consequence measurement | Key findings (SA) | Funding source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Hashimoto et al. (2001) [34] ENG | MD-MDIive consultation rural hospitals | Emergency radiotherapy | ProsCoh | CBA | 6/3 | Health care system | 1 y (no need) Not specified | 1073 | Initial system and operational costs for one university hospital and 10 rural hospitals including consultation fee | Recovery rate of non-ambulant patients, % of avoiding hospitalization | Cost-saving 4.67<BCR<13.4 | Not specified |
SA: not perfumed | ||||||||||||
Takada et al. (2003) [37] ENG | MD-MDIive consultation rural hospitals | Diagnostic radiology | DiagAcc | CMA | 6/3 | Health provider | 1 y (no need) Not specified | 500 | Only cost of films used for diagnosis and consultation fees are shown | Diagnosis accuracy, % of avoiding unnecessary enhanced CT | Cost-saving ($144 per reading) | Not specified |
No initial cost shown | SA: not perfumed | |||||||||||
Dekio et al. (2010) [35] ENG | MD-MDIive consultation rural hospitals | Dermatology | DiagAcc | CMA | 9/1 | Health provider | 1 wk (no need) Not specified | 107 | Initial system cost and monthly costs including medical staff’s fees, travel costs, and overhead office fee | Screen image diagnoses, travel time and cost saved | Cost-saving BCR = 1.53 (when travel/consultation time = 60 min/5 min) ($330 saving per case per week)2 | MEXT |
SA: 2-way | ||||||||||||
Tanikawa et al. (2010) [49] JPN | MD-MDIive consultation rural clinics | Pediatric primary care | Survey | WTP estimation | 2/7 | Societal | 1 d (no need) Not specified | 263 | N/A | Patients’ WTP for telemedicine use between remote primary pediatrician and university hospital | WTP = $31-34 per emergency department visit | Not specified |
SA: not perfumed | ||||||||||||
Miyahara et al. (2006) [38] ENG | MD-MD stored nation-wide | Teleradiology, telepathology | Survey | WTP estimation | 1/8 | Health provider | 1 y (no need) Not specified | 622 | N/A | Medical institutions’ WTP, for teleradiology, pathology, consultation (MD-MD) | WTP=$489 per person per year for teleradiology, $1063 for telepathology | MEXT, Postal |
Saving Funds | ||||||||||||
SA: not perfumed | ||||||||||||
Tsuji et al. (2006) [39] ENG | MD-MD stored nation-wide | Teleradiology, telepathology | Survey | WTP estimation | 1/8 | Health provider | 1 y (no need) Not specified | 622 | N/A | Medical institutions’ WTP, for teleradiology, pathology, consultation (MD-MD) | WTP=$510 per person per year for teleradiology, $1111 for telepathology | JSPS, MHLW, |
Okawa | ||||||||||||
Telecom | ||||||||||||
Fecundation, | ||||||||||||
Postal Saving | ||||||||||||
SA: not perfumed | Funds | |||||||||||
Aoki et al. (2006) [36] ENG | MD-Pt live rural home | Palliative care | RetCoh | CMA | 9/0 | Health care system | 1 y (no need) | 100 | Initial system cost and monthly costs including medical staff’s fees and travel costs. | Patients' satisfaction (qualitative), travel time and cost saved | BCR = 1.93 ($5000 saving per case per year)3 | MHLW |
5 y depreciation | SA: 1-way and 2-way | |||||||||||
Tsuji et al. (2002) [48] JPN | MD-Pt, stored rural home | Elderly with chronic diseases | RetCoh | CBA | 8/2 | Societal | 6-11 y (4%) | 405 | Initial system and device cost and operational costs including labor fees. | Users’ health consciousness, anxiety, and WTP for telehomecare service | Cost-saving | MHLW |
6y depreciaticDn | BCR (6 y)=1.07 | |||||||||||
BCR (11 y)=1.28 | ||||||||||||
SA: not perfumed | ||||||||||||
Tsuji et al. (2003) [40] ENG | MD-Pt stored rural home | Elderly with chronic diseases | RetCoh | CBA | 8/2 | Societal | 6 y (4%) | 2333 | Initial system and device cost and operational costs including labor fees. | Users’ health consciousness, anxiety, and WTP for telehomecare service | BCR in 4 regions ranged from 0.54 to 1.07 | MEXT |
6y depreciaticDn | SA: not perfumed | |||||||||||
Ito et al. (2003) [46] JPN | MD-Pt stored rural home | Elderly with chronic diseases | Survey | WTP estimation | 2/7 | Societal | 1 mo (no need) | 498 | N/A | Users’ health consciousness, anxiety, and WTP for telehomecare service | WTP=$288 per case per year for telehomecare; no difference between 2 towns after adjustment | Not specified |
Not specified | SA: not perfumed | |||||||||||
Osaka et al. (2003) [47] JPN | MD-Pt stored rural home | Elderly with chronic diseases | Survey | WTP estimation | 1/8 | Societal | 1 mo (no need) | 348 | N/A | Users’ health consciousness, anxiety, and WTP for telehomecare service | WTP=$480 per case per year for telehome care | Not specified |
Not specified | SA: not perfumed | |||||||||||
Tsuji et al. (2003) [41] ENG | MD-Pt, stored rural home | Elderly with chronic diseases | Survey | WTP estimation | 1/8 | Societal | 1 mo (no need) | 348 | N/A | Users’ health consciousness, anxiety, and WTP for telehomecare service | WTP=$520 per case per year for telehome care | MEXT |
Not specified | SA: not perfumed | |||||||||||
Homma et al. (2012) [42] ENG | MD-Pt stored urban home | Elderly with chronic diseases | Survey | WTP estimation | 1/8 | Societal | 1 mo (no need) | 102 | N/A | Users’ WTP for monitoring service | WTP=$109 per case per year for chronic care | Omron Health Care Co. |
Not specified | SA: not perfumed | |||||||||||
Akematsu et al. (2009) [43] ENG | PhNrs-Pt rural home | Elderly with chronic diseases | RetCoh | Benefit estimation | 3/7 | Societal | 10 y (not applied) | 862 | N/A | Medical expenditure saved by telehomecare based on receipts data of NHI | Savings of $148 per case per year for outpatient care with lifestyle-related illness | MHLW, MEXT, JSPS |
Not specified | SA: not perfumed | |||||||||||
Akematsu et al. (2010) [27] JPN | PhNrs-Pt rural home | Elderly with chronic diseases | RetCoh | Benefit estimation | 3/6 | Societal | 1 y (no need) | 862 | N/A | Medical expenditure saved by telehomecare based on receipts data of NHI | Savings $212-371 per case per year for outpatient care with heart disease, high blood pressure, and diabetes | Not specified |
Not specified | SA: not perfumed | |||||||||||
Akematsu et al. (2012) [44] ENG | PhNrs-Pt rural home | Elderly with chronic diseases | RetCoh | Benefit estimation | 3/5 | Societal | 1 y (no need) | 408 | N/A | Medical expenditure saved by telehomecare based on receipts data of NHI | Savings of $247-387 per case per year for outpatient care with chronic diseases | Not specified |
Not specified | SA: not perfumed | |||||||||||
Akematsu et al. (2013) [45] ENG | PhNrs-Pt rural home | Elderly with chronic diseases | RetCoh | Benefit estimation | 3/7 | Societal | 9 y (no need) | 519 | N/A | Medical expenditure saved by telehomecare based on receipts data of NHI | Savings of $629 per case per year for outpatient care with chronic diseases | Not specified |
Not specified | SA: not perfumed |
Ref, reference number; Econ, economic; Eval, evaluation; SA, sensitivity analysis; ENG, English; JPN, Japanese; N/A, not applicable; NHI, National Health Insurance; BCR, benefit-to-cost ratio; CT, computed tomography; MD, medical doctor; Pt, patient, PhNrs, public health nurse; ProsCoh, prospective cohort; DiagAcc, diagnostic accuracy study; RetCoh, retrospective cohort; CBA, cost-benefit analysis; CMA, cost-minimization analysis; WTP, willingness-to-pay; MEXT, Japan’s Ministry of Education, Culture Sports, Science and Technology; MHLW, Japan’s Ministry of Health, Labor, and Welfare; JSPS, Japan Society for the Promotion of Science.
1 Quality assessment of Econ Eval: (total number of “yes”/ total number of “no”) of assessment criteria in the checklist in Table 2, (yes/no) detailed in Table 4.
2 Difference between “live interactive teledermatology” and “conventional clinic.”
3 Difference between “telepalliative care combined homecare” and “homecare with eight physician visits per month, without telemedicine” when 10 patients treated simultaneously.
Database |
Keywords for search |
---|---|
PubMed/MEDLINE | ("costs and cost analysis"[MeSH terms] OR "cost benefit analysis"[MeSH terms] OR "cost effectiveness" OR "cost utility") AND ("telemedicine"[MeSH terms] OR telecare OR telehealth OR e-health) AND Japan |
Web of Science | TS = ("cost$analysis" OR "cost*benefit" OR "cost*effectiveness" OR "cost*utility" OR "economic evaluation") AND TS = (telemedicine OR tele*care OR tele*health OR e*health) AND TS = (Japan*) |
IEEE Xplore | ("cost analysis" OR "cost benefit" OR "cost effectiveness" OR "cost utility" OR "economic evaluation") AND (telemedicine OR telec are OR telehealth OR e-health) AND Japan |
Ichushi-Web |
(in Japanese) Within "Original Article" category, used ("cost analysis" OR "cost benefit" OR "cost effectiveness" OR "cost utility" OR "economic evaluation") AND (telemedicine OR telecare OR telehealth OR e-health) |
CiNii Articles |
(in Japanese) ("cost analysis" OR "cost benefit" OR "cost effectiveness" OR "cost utility" OR "economic evaluation") AND (telemedicine OR telecare OR telehealth OR e-health) |
Contain items | ||
---|---|---|
1. Was a well-defined question posed in answerable form? | ||
1.1. | Did the study examine both costs and effects of the service(s) or programme(s) over an appropriate time horizon? | |
1.2. | Did the study involve a comparison of alternatives? | |
1.3. | Was a viewpoint for the analysis stated and was the study placed in any particular decision-making context? | |
1.4. | Where the patient population and any relevant subgroups adequately defined? | |
2. Was a comprehensive description of the competing alternatives given (i.e. can you tell who did what to whom, where, and how often)? | ||
2.1. | Were there any important alternatives omitted? | |
2.2. | Was (should) a do-nothing alternative (be) considered? | |
2.3. | Were relevant alternatives identified for the patient subgroups? | |
3. Was the effectiveness of the programme or services established? | ||
3.1. | Was this done through a randomised, controlled clinical trial? If so, did the trial protocol reflect what would happen in regular practice? | |
3.2. | Was effectiveness established through an overview of clinical studies? If so, were the search strategy and rules for inclusion or exclusion outlined? | |
3.3. | Were observational data or assumptions used to establish effectiveness? If so, were any potential biases recognized? | |
4. Were all the important and relevant costs and consequences for each alternative identified? | ||
4.1. | Was the range wide enough for the research question at hand? | |
4.2. | Did it cover all relevant viewpoints? (Possible viewpoints include the community or social viewpoint, and those of patients and third-party payers. Other viewpoints may also be relevant depending upon the particular analysis.) | |
4.3. | Were the capital costs, as well as operating costs, included? | |
5. Were costs and consequences measured accurately in appropriate physical units (e.g. hours of nursing time, number of physician visits, lost work-days, gained life years)? | ||
5.1. | Were the sources of resource utilization described and justified? | |
5.2. | Were any of the identified items omitted from measurement? If so, does this mean that they carried no weight in the subsequent analysis? | |
5.3. | Were there any special circumstances (e.g., joint use of resources) that made measurement difficult? Were these circumstances handled appropriately? | |
6. Were the cost and consequences valued credibly? | ||
6.1. | Were the sources of all values clearly identified? (Possible sources include market values, patient or client preferences and views, policy-makers’ views and health professionals’ judgements) | |
6.2. | Were market values employed for changes involving resources gained or depleted? | |
6.3. | Where market values were absent (e.g. volunteer labour), or market values did not reflect actual values (such as clinic space donated at a reduced rate), were adjust- ments made to approximate market values? | |
6.4. | Was the valuation of consequences appropriate for the question posed (i.e. has the appropriate type or types of analysis – cost-effectiveness, cost-benefit, cost-utility – been selected)? | |
7. Were costs and consequences adjusted for differential timing? | ||
7.1. | Were costs and consequences that occur in the future ‘discounted’ to their present values? | |
7.2. | Was there any justification given for the discount rate used? | |
8. Was an incremental analysis of costs and consequences of alternatives performed? | ||
8.1. | Were the additional (incremental) costs generated by one alternative over another compared to the additional effects, benefits, or utilities generated? | |
9. Was allowance made for uncertainty in the estimates of costs and consequences? | ||
9.1. | If patient-level data on costs or consequences were available, were appropriate statistical analyses performed? | |
9.2. | If a sensitivity analysis was employed, was justification provided for the form(s) of sensitivity analysis employed and the ranges or distributions of values (for key study parameters)? | |
9.3. | Were the conclusions of the study sensitive to the uncertainty in the results, as quantified by the statistical and/or sensitivity analysis? | |
9.4. | Was heterogeneity in the patient population recognized, for example by presenting study results for relevant subgroups? | |
10. Did the presentation and discussion of study results include all issues of concern to users? | ||
10.1. | Were the conclusions of the analysis based on some overall index or ratio of costs to consequences (e.g. cost-effectiveness ratio)? If so, was the index interpreted intel- ligently or in a mechanistic fashion? | |
10.2. | Were the results compared with those of others who have investigated the same question? If so, were allowances made for potential differences in study methodol- ogy? | |
10.3. | Did the study discuss the generalisability of the results to other settings and patient/client groups? | |
10.4. | Did the study allude to, or take account of, other important factors in the choice or decision under consideration (e.g. distribution of costs and consequences, or relevant ethical issues)? | |
10.5. | Did the study discuss issues of implementation, such as the feasibility of adopting the ‘preferred’ programme given existing financial or other constraints, and whether any freed resources could be redeployed to other worthwhile programmes? | |
10.6. | Were the implications of uncertainty for decision-making, including the need for future research, explored? |
Author (published year) [Ref] language | Service setting & location | Clinical discipline | Study design | Econ Eval type | Quality assess |
Perspective | Time horizon (discount) depreciation | Sample size | Cost measurement | Consequence measurement | Key findings (SA) | Funding source |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Hashimoto et al. (2001) [34] ENG | MD-MDIive consultation rural hospitals | Emergency radiotherapy | ProsCoh | CBA | 6/3 | Health care system | 1 y (no need) Not specified | 1073 | Initial system and operational costs for one university hospital and 10 rural hospitals including consultation fee | Recovery rate of non-ambulant patients, % of avoiding hospitalization | Cost-saving 4.67<BCR<13.4 | Not specified |
SA: not perfumed | ||||||||||||
Takada et al. (2003) [37] ENG | MD-MDIive consultation rural hospitals | Diagnostic radiology | DiagAcc | CMA | 6/3 | Health provider | 1 y (no need) Not specified | 500 | Only cost of films used for diagnosis and consultation fees are shown | Diagnosis accuracy, % of avoiding unnecessary enhanced CT | Cost-saving ($144 per reading) | Not specified |
No initial cost shown | SA: not perfumed | |||||||||||
Dekio et al. (2010) [35] ENG | MD-MDIive consultation rural hospitals | Dermatology | DiagAcc | CMA | 9/1 | Health provider | 1 wk (no need) Not specified | 107 | Initial system cost and monthly costs including medical staff’s fees, travel costs, and overhead office fee | Screen image diagnoses, travel time and cost saved | Cost-saving BCR = 1.53 (when travel/consultation time = 60 min/5 min) ($330 saving per case per week) |
MEXT |
SA: 2-way | ||||||||||||
Tanikawa et al. (2010) [49] JPN | MD-MDIive consultation rural clinics | Pediatric primary care | Survey | WTP estimation | 2/7 | Societal | 1 d (no need) Not specified | 263 | N/A | Patients’ WTP for telemedicine use between remote primary pediatrician and university hospital | WTP = $31-34 per emergency department visit | Not specified |
SA: not perfumed | ||||||||||||
Miyahara et al. (2006) [38] ENG | MD-MD stored nation-wide | Teleradiology, telepathology | Survey | WTP estimation | 1/8 | Health provider | 1 y (no need) Not specified | 622 | N/A | Medical institutions’ WTP, for teleradiology, pathology, consultation (MD-MD) | WTP=$489 per person per year for teleradiology, $1063 for telepathology | MEXT, Postal |
Saving Funds | ||||||||||||
SA: not perfumed | ||||||||||||
Tsuji et al. (2006) [39] ENG | MD-MD stored nation-wide | Teleradiology, telepathology | Survey | WTP estimation | 1/8 | Health provider | 1 y (no need) Not specified | 622 | N/A | Medical institutions’ WTP, for teleradiology, pathology, consultation (MD-MD) | WTP=$510 per person per year for teleradiology, $1111 for telepathology | JSPS, MHLW, |
Okawa | ||||||||||||
Telecom | ||||||||||||
Fecundation, | ||||||||||||
Postal Saving | ||||||||||||
SA: not perfumed | Funds | |||||||||||
Aoki et al. (2006) [36] ENG | MD-Pt live rural home | Palliative care | RetCoh | CMA | 9/0 | Health care system | 1 y (no need) | 100 | Initial system cost and monthly costs including medical staff’s fees and travel costs. | Patients' satisfaction (qualitative), travel time and cost saved | BCR = 1.93 ($5000 saving per case per year) |
MHLW |
5 y depreciation | SA: 1-way and 2-way | |||||||||||
Tsuji et al. (2002) [48] JPN | MD-Pt, stored rural home | Elderly with chronic diseases | RetCoh | CBA | 8/2 | Societal | 6-11 y (4%) | 405 | Initial system and device cost and operational costs including labor fees. | Users’ health consciousness, anxiety, and WTP for telehomecare service | Cost-saving | MHLW |
6y depreciaticDn | BCR (6 y)=1.07 | |||||||||||
BCR (11 y)=1.28 | ||||||||||||
SA: not perfumed | ||||||||||||
Tsuji et al. (2003) [40] ENG | MD-Pt stored rural home | Elderly with chronic diseases | RetCoh | CBA | 8/2 | Societal | 6 y (4%) | 2333 | Initial system and device cost and operational costs including labor fees. | Users’ health consciousness, anxiety, and WTP for telehomecare service | BCR in 4 regions ranged from 0.54 to 1.07 | MEXT |
6y depreciaticDn | SA: not perfumed | |||||||||||
Ito et al. (2003) [46] JPN | MD-Pt stored rural home | Elderly with chronic diseases | Survey | WTP estimation | 2/7 | Societal | 1 mo (no need) | 498 | N/A | Users’ health consciousness, anxiety, and WTP for telehomecare service | WTP=$288 per case per year for telehomecare; no difference between 2 towns after adjustment | Not specified |
Not specified | SA: not perfumed | |||||||||||
Osaka et al. (2003) [47] JPN | MD-Pt stored rural home | Elderly with chronic diseases | Survey | WTP estimation | 1/8 | Societal | 1 mo (no need) | 348 | N/A | Users’ health consciousness, anxiety, and WTP for telehomecare service | WTP=$480 per case per year for telehome care | Not specified |
Not specified | SA: not perfumed | |||||||||||
Tsuji et al. (2003) [41] ENG | MD-Pt, stored rural home | Elderly with chronic diseases | Survey | WTP estimation | 1/8 | Societal | 1 mo (no need) | 348 | N/A | Users’ health consciousness, anxiety, and WTP for telehomecare service | WTP=$520 per case per year for telehome care | MEXT |
Not specified | SA: not perfumed | |||||||||||
Homma et al. (2012) [42] ENG | MD-Pt stored urban home | Elderly with chronic diseases | Survey | WTP estimation | 1/8 | Societal | 1 mo (no need) | 102 | N/A | Users’ WTP for monitoring service | WTP=$109 per case per year for chronic care | Omron Health Care Co. |
Not specified | SA: not perfumed | |||||||||||
Akematsu et al. (2009) [43] ENG | PhNrs-Pt rural home | Elderly with chronic diseases | RetCoh | Benefit estimation | 3/7 | Societal | 10 y (not applied) | 862 | N/A | Medical expenditure saved by telehomecare based on receipts data of NHI | Savings of $148 per case per year for outpatient care with lifestyle-related illness | MHLW, MEXT, JSPS |
Not specified | SA: not perfumed | |||||||||||
Akematsu et al. (2010) [27] JPN | PhNrs-Pt rural home | Elderly with chronic diseases | RetCoh | Benefit estimation | 3/6 | Societal | 1 y (no need) | 862 | N/A | Medical expenditure saved by telehomecare based on receipts data of NHI | Savings $212-371 per case per year for outpatient care with heart disease, high blood pressure, and diabetes | Not specified |
Not specified | SA: not perfumed | |||||||||||
Akematsu et al. (2012) [44] ENG | PhNrs-Pt rural home | Elderly with chronic diseases | RetCoh | Benefit estimation | 3/5 | Societal | 1 y (no need) | 408 | N/A | Medical expenditure saved by telehomecare based on receipts data of NHI | Savings of $247-387 per case per year for outpatient care with chronic diseases | Not specified |
Not specified | SA: not perfumed | |||||||||||
Akematsu et al. (2013) [45] ENG | PhNrs-Pt rural home | Elderly with chronic diseases | RetCoh | Benefit estimation | 3/7 | Societal | 9 y (no need) | 519 | N/A | Medical expenditure saved by telehomecare based on receipts data of NHI | Savings of $629 per case per year for outpatient care with chronic diseases | Not specified |
Not specified | SA: not perfumed |
Reference number |
|||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
34 | 37 | 35 | 49 | 38 | 39 | 36 | 48 | 40 | 46 | 47 | 41 | 42 | 43 | 27 | 44 | 45 | |
Well-defined econ question (viewpoint, comparison) | No | No | Yes | No | No | No | Yes | Yes | Yes | No | No | No | No | No | No | No | No |
Competing alternatives | Yes | Yes | Yes | Yes | No | No | Yes | Yes | Yes | Yes | No | No | No | Yes | Yes | Yes | Yes |
Effectiveness of the program | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Costs and consequences inclusion | Yes | Yes | Yes | No | No | No | Yes | Yes | Yes | No | No | No | No | No | No | No | No |
Costs and consequences measurement | Yes | Yes | Yes | No | No | No | Yes | Yes | Yes | No | No | No | No | No | No | No | No |
Cost and consequences value credibly | Yes | Yes | Yes | No | No | No | Yes | Yes | Yes | No | No | No | No | No | No | No | No |
Adjusted for timing and discount | N/A | N/A | No | N/A | N/A | N/A | N/A | Yes | Yes | N/A | N/A | N/A | N/A | No | N/A | N/A | No |
Incremental analysis | Yes | Yes | Yes | No | No | No | Yes | Yes | Yes | No | No | No | No | Yes | Yes | Yes | Yes |
Allowance for uncertainty in the estimates | No | No | Yes | No | No | No | Yes | No | No | No | No | No | No | No | No | No | No |
Study results including all issues of concern | No | No | Yes | No | No | No | Yes | No | No | No | No | No | No | No | No | N/A | No |
# of “yes” | 6 | 6 | 9 | 2 | 1 | 1 | 9 | 8 | 8 | 2 | 1 | 1 | 1 | 3 | 3 | 3 | 3 |
# of “no” | 3 | 3 | 1 | 7 | 8 | 8 | 0 | 2 | 2 | 7 | 8 | 8 | 8 | 7 | 6 | 6 | 7 |
The index period was 2000-2014 except for IEEE Xplore, which only allowed a search of journals published after 2002. For Japanese databases, relevant keywords were used, and the word “Japan” was not used.
Assessors are asked to check either “yes,” “no,” or “not applicable” for each of the 10 subheadings according to the relative importance subjectively conferred to each item under each subheading.
Ref, reference number; Econ, economic; Eval, evaluation; SA, sensitivity analysis; ENG, English; JPN, Japanese; N/A, not applicable; NHI, National Health Insurance; BCR, benefit-to-cost ratio; CT, computed tomography; MD, medical doctor; Pt, patient, PhNrs, public health nurse; ProsCoh, prospective cohort; DiagAcc, diagnostic accuracy study; RetCoh, retrospective cohort; CBA, cost-benefit analysis; CMA, cost-minimization analysis; WTP, willingness-to-pay; MEXT, Japan’s Ministry of Education, Culture Sports, Science and Technology; MHLW, Japan’s Ministry of Health, Labor, and Welfare; JSPS, Japan Society for the Promotion of Science. Quality assessment of Econ Eval: (total number of “yes”/ total number of “no”) of assessment criteria in the checklist in Table 2, (yes/no) detailed in Difference between “live interactive teledermatology” and “conventional clinic.” Difference between “telepalliative care combined homecare” and “homecare with eight physician visits per month, without telemedicine” when 10 patients treated simultaneously.
N/A, not applicable. Each column corresponds to each of the sub-headings shown in